COMP360 Psilocybin for TRD Brings Rapid Relief, Lasting Benefit | Steve Levine, MD скачать в хорошем качестве

COMP360 Psilocybin for TRD Brings Rapid Relief, Lasting Benefit | Steve Levine, MD

In a phase 3 study, Compass Pathways' synthetic psilocybin therapy, COMP360, demonstrates next-day antidepressant effects and potential 6-month durability for treatment-resistant depression (TRD). In this interview, Steve Levine, MD, chief patient officer at Compass Pathways, explains key findings from the phase 3 COMP005 and COMP006 trials, including the –3.8 MADRS point reduction vs control at week 6, rapid symptom improvement observed by day 2, and sustained benefits through 26 weeks with 1 or 2 doses. Read more about the study here: https://www.hcplive.com/view/comp360-... More MDD coverage: https://www.hcplive.com/clinical/majo... Key Highlights: 00:07: Clinically meaningful difference on MADRS 0:44: Effect size of COMP006 vs other TRD trials 02:16: Rapid onset of COMP360 03:35: Maintaining benefit through week 6 after just 1 or 2 doses 04:19: 26-week COMP005 durability data 05:20: MADRS response rate 07:05: COMP360 vs esketamine #TRD #treatmentresistantdepression #depression #mdd #psychedelictherapy